Hjem › Multipelt myelom › Florida › Tampa
Kliniske studier for Multipelt myelom i Tampa, FL
15 studier for Multipelt myelom søker deltakere på steder i og rundt Tampa (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
RekruttererFase 1
- Moffitt Cancer Center /ID# 279068, Tampa
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RekruttererFase 3
- Research Site, Tampa
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 3
- Moffit Cancer center, Tampa
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RekruttererFase 4
- Moffitt Cancer Center, Tampa
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
RekruttererFase 1
- Moffitt Cancer Center, Tampa
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 2
- Moffitt Cancer Center, Tampa
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
RekruttererFase 1
- Moffitt Cancer Center, Tampa
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 1/2
- Research Site, Tampa
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RekruttererFase 1/2
- Research Site, Tampa
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RekruttererFase 3
- Research Site, Tampa
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
RekruttererFase 1/2
- Moffitt Cancer Center /ID# 272628, Tampa
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RekruttererFase 3
- Moffitt at Memorial Healthcare System, Tampa
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
RekruttererFase 1/2
- Moffitt Cancer Center - McKinley Drive, Tampa
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekruttererFase 1/2
- Moffitt Cancer Center, Tampa
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
RekruttererFase 1
- Moffitt Cancer Center, Tampa
Multipelt myelom-studier i andre byer
- New York City, NY60 studier
- Boston, MA42 studier
- Atlanta, GA41 studier
- Houston, TX38 studier
- Durham, NC37 studier
- Nashville, TN32 studier
- Denver, CO27 studier
- Rochester, MN24 studier
- St. Louis, MO24 studier
- Columbus, OH24 studier
- Baldwin Park, CA23 studier
- Chicago, IL22 studier
Andre studier i Tampa
- Ikke-småcellet lungekreft51 studier
- Brystkreft43 studier
- Kreft (alle typer)39 studier
- Kolorektal kreft33 studier
- Metastatisk kreft29 studier
- Lungekreft29 studier
- Akut myelogen leukemi29 studier
- Pankreaskreft26 studier
- Eggstokkreft21 studier
- Myelodysplastiske syndromer19 studier
- Melanom19 studier
- Hjertesvikt18 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.